Actinium Seeks to Disrupt As Radioligand Candidate Succeeds In Pivotal Pre-Transplant AML Trial
Executive Summary
The US firm’s lead asset has impressed as a conditioning regimen for AML patients undergoing bone marrow transplant, boding well for an ongoing US filing as the firm works to disrupt the transplant space across a range of blood cancers.
You may also be interested in...
Actinium clears path for fundraising and listing to advance alpha/MAb therapies
The Newark, New Jersey-based privately held company Actinium Pharmaceuticals, which is developing drugs combining cell-targeting antibodies with alpha-emitting radioisotopes to treat cancer, has secured approval from its shareholders to raise up to $25 million and seek a public listing.
Aridis' Monoclonal Antibody Rouses Analyst Optimism Despite Pneumonia Phase III Miss
The US biotech’s lead candidate missed the mark in a Phase III hospital-related pneumonia trial due to low recruitment affected by macroeconomic headwinds but analysts retain high hopes for another upcoming study.
Grey Wolf Raises $49m To Bring ‘Tumor Unmasking’ Candidate To Clinic
The UK biotech will use the funds to advance the development of its first-in-class ERAP1 inhibitor, which could circumvent the limitations of poor tumor visibility and T cell exhaustion.